You are here

Kalytera Therapeutics Announces Adjournment of 2018 Annual and Special Meeting

SAN FRANCISCO and TEL AVIV, Israel, July 27, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (the “Company”, or “Kalytera”) (TSXV:KALY) (OTCQB:KALTF) announced today that the annual and special meeting of Kalytera shareholders, scheduled for, and convened on, July 27, 2018 was adjourned due to the lack of requisite quorum.

In accordance with the articles of the Company, the annual and special meeting has been adjourned to Friday, August 3, 2018 at 10:00 a.m. at Torys LLP, 79 Wellington St. West, 33rd Floor, TD South Tower, Toronto, Ontario  (the “Adjourned Meeting”).

The Company’s articles provide that the quorum for the transaction of business at a meeting of shareholders is two shareholders represented in person or by proxy holding in aggregate at least 10% of the issued shares.

At the Adjourned Meeting to be held on August 3, 2018, the Company’s articles provide that if the 10% quorum is not present then the shareholders represented in person or by proxy at the meeting shall nonetheless constitute a quorum.

The Company’s notice of meeting, information circular and form of proxy in respect of the annual meeting available on SEDAR at and mailed to the Kalytera shareholders remain unchanged.

Forms of proxy which have been duly submitted and were valid for the Meeting will still be valid at the Adjourned Meeting unless properly revoked.

The forms of proxy that accompanied the notice of meeting and information circular which were sent to the shareholders can still be used for the Adjourned Meeting.  Any registered shareholder who wishes to appoint a proxy to attend and vote at the Adjourned Meeting and has not yet done so should note that a valid form of proxy may now be received by TSX Trust Company, 200 University Avenue, Suite 300, Toronto, Ontario, M5H 4H1 up to 10:00 a.m. (Toronto time) on Wednesday, August 1, 2018.  Proxies received after this time may not be accepted; however the chair of the Adjourned Meeting may determine, in his sole discretion, to waive this deadline or to accept a proxy that is delivered in person to the chair at the Adjourned Meeting as to any matter in respect of which a vote has not already been cast.

About Kalytera Therapeutics

Kalytera Therapeutics, Inc. is pioneering the development of cannabidiol (“CBD”) therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of CBD medicines for a range of important unmet medical needs, with an initial focus on graft versus host disease and treatment of acute and chronic pain.

Cautionary Statements

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

Robert Farrell
President, CEO
(888) 861-2008

Friday, July 27, 2018 - 17:08